Labeling of sarcoma associated monoclonal antibody with 111In, 67Ga and 125I

Lavie, E.; Boazi, M.; Weininger, J.; Bitton, M.; Yosilevski, G.; Front, Dov; Hirshaut, Yashar; Robinson, Eliezer; Bartal, Arie H.

doi:10.1016/s0167-8140(87)80166-4

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 The latter two are good examples of the potential benefit of antibody-guided systemic radionuclide-targeted therapy. [39][40][41][42][43][44][45][46] In addition, several other radiopharmaceuticals for radio-immunotherapy of tumors have been introduced into clinical trials. More detailed information on these clinical trials is presented in the review of Gudkov and coworkers (Table 3).…”

Section: Introductionmentioning

confidence: 99%

“…While Quadramet and Metastron consist of radioactive samarium ( 153 Sm) complexed to a tetraphosphonate chelator and a strontium-89 chloride ( 89 SrCl 2 ) injection, respectively, Zevalin and Bexxar are radiolabeled murine antibodies, directed against the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes . The latter two are good examples of the potential benefit of antibody-guided systemic radionuclide-targeted therapy. − In addition, several other radiopharmaceuticals for radioimmunotherapy of tumors have been introduced into clinical trials. More detailed information on these clinical trials is presented in the review of Gudkov and co-workers (Table ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dendrimers as Innovative Radiopharmaceuticals in Cancer Radionanotherapy

2016

View full text Add to dashboard Cite

Radiotherapy is one of the most commonly used cancer treatments, with an estimate of 40% success that could be improved further if more efficient targeting and retention of radiation at the tumor site were achieved. This review focuses on the use of dendrimers in radionanotherapy, an emerging technology aimed to improve the efficiency of radiotherapy by implementing nanovectorization, an already established praxis in drug delivery and diagnosis. The labeling of dendrimers with radionuclides also aims to reduce the dose of radiolabeled materials and, hence, their toxicity and tumor resistance. Examples of radiolabeled dendrimers with alpha, beta, and Auger electron emitters are commented, along with the use of dendrimers in boron neutron capture therapy (BNCT). The conjugation of radiolabeled dendrimers to monoclonal antibodies for a more efficient targeting and the application of dendrimers in gene delivery radiotherapy are also covered.

show abstract